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Pseudomonas aeruginosa infection is associated with poorer outcomes in non-cystic fibrosis
bronchiectasis. It is unknown whether early eradication improves outcomes. This retrospective
study assessed clinical and microbiological outcomes of eradication therapy following initial
Pseudomonas infection.
All patients undergoing Pseudomonas eradication therapy from 2004 to 2010 were identified
retrospectively and assessed for microbiological eradication, exacerbation frequency, hospital
admissions, clinical symptoms and lung function.
30 patients were identified with median follow-up time 26.4 months. Eradication therapy
involved intravenous antibiotics (n Z 12), intravenous antibiotics followed by oral ciprofloxa-
cin (n Z 13) or ciprofloxacin alone (n Z 5), combined with 3 months of nebulised colistin.
Pseudomonas was initially eradicated from sputum in 24 patients (80.0%). 13/24 patients re-
mained Pseudomonas-free and 11/24 were subsequently reinfected (median time 6.2 months).
Exacerbation frequency was significantly reduced from 3.93 per year pre-eradication and 2.09
post-eradication (p Z 0.002). Admission rates were similar, at 0.39 per year pre-eradication
and 0.29 post-eradication (p Z NS). 20/30 patients reported initial clinical improvement,
whilst at one-year follow up, 19/21 had further improved or remained stable. Lung function
was unchanged.
This study demonstrates that Pseudomonas can be eradicated from a high proportion of
patients, which may lead to prolonged clearance and reduced exacerbation rates. This impor-
tant outcome requires confirmation in a prospective study.
ª 2011 Elsevier Ltd. All rights reserved.1225 825408; fax: þ44 0 1225 824175.
@nhs.net (J. Suntharalingam).
1 Elsevier Ltd. All rights reserved.
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Bronchiectasis is a disease characterised by dilated
bronchi, airway inflammation and bacterial colonisation.
Recurrent exacerbations caused by bacterial infection lead
to increased morbidity. Chronic infection with Pseudo-
monas aeruginosa commonly occurs as the disease prog-
resses and is associated with increased symptoms,1
decreased quality of life2 and possibly a decline in
FEV1.3,4 Treatment of exacerbations in patients infected
with Pseudomonas often requires hospital admission for
intravenous antibiotics as the organism is frequently resis-
tant to oral antibiotics.
In patients with cystic fibrosis (CF), early treatment of
Pseudomonas following first culture is well established as it
reduces risk of chronic colonisation, which in this pop-
ulation is similarly associated with poorer outcomes.5
Several small randomised controlled trials in CF patients
showed that microbiological eradication was more likely
following treatment with combined nebulised colistin and
oral ciprofloxacin, or nebulised tobramycin,6e9 although
the most effective treatment strategy has not been
determined.5 Based on this, it could be postulated that
early treatment in non-CF bronchiectasis would also
improve outcomes. Indeed, recent British Thoracic Society
guidelines recommend attempting early Pseudomonas
eradication, initially with high dose oral ciprofloxacin, and
second line treatment with further oral, intravenous or
nebulised anti-Pseudomonal antibiotics.10 Despite this
however, there are no existing studies non-CF bronchiec-
tasis assessing eradication therapy in recently infected
patients.
Since 2004, our unit has had a policy of early Pseudo-
monas eradication therapy in patients with non-CF bron-
chiectasis. This retrospective study examines the clinical
and microbiological outcomes of this treatment strategy.Methods
Study centre
The study was carried out in a UK District General Hospital
serving a population of 500,000. The Respiratory Unit is well
established and offers a secondary care service for all
respiratory conditions, including non-CF bronchiectasis.
Patient selection
Patients with bronchiectasis who had undergone “Pseu-
domonas eradication therapy” were identified retrospec-
tively from electronic case records at the Royal United
Hospital, Bath for the period January 2004 to January
2010. Patients were under standard hospital clinic follow
up. Patients were included in the study if they had: (i)
a diagnosis of bronchiectasis as based on clinical presen-
tation and HRCT findings; and (ii) first attempt at Pseu-
domonas eradication as per protocol. Decision to
commence eradication therapy was at the clinician’s
discretion, typically after the second isolate of Pseudo-
monas from sputum. Patients were also included in thestudy if they had had more than two cultures of Pseudo-
monas but had not previously had eradication therapy.
Patients who were commenced on regular nebulised anti-
pseudomonal antibiotics without concurrent intravenous
or oral antibiotics were not included.
Pseudomonas eradication protocol
Intravenous regime: Intravenous gentamicin 4 mg/kg
plus ceftazidime 2 g three times daily for 2-weeks, followed
by nebulised colistin 2 megaunits twice daily for 3 months
þ/ oral ciprofloxacin 500 mg twice daily for 3 months.
Oral regime: Ciprofloxacin 500 mg twice daily for 3
months plus nebulised colistin 2 megaunits twice daily for 3
months.
Variations from the protocol occurred mainly because
of drug allergy or intolerance, and alternative anti-
pseudomonal antibiotics were used at the clinician’s
discretion.
Sputum cultures
Sputum was analysed in the hospital microbiology labora-
tory as per standard methods, including antibiotic sensi-
tivities.11 Sputum samples from patients with
bronchiectasis were highlighted to the laboratory to ensure
appropriate culture for Pseudomonas. Following comple-
tion of treatment, eradication of Pseudomonas was defined
as a negative culture on next sputum sample taken.
Recurrence was defined as the first positive culture
following treatment. Sputum cultures were collected at
next point of clinical contact following treatment. Pseu-
domonas antibiotic sensitivities for pairs of sputum samples
before and after eradication therapy for the patients in
whom eradication was successful, but who were subse-
quently recolonised, were recorded, to determine if erad-
ication therapy resulted in resistant strains.
Exacerbation frequency and hospital admissions
Number of episodes was recorded for the years pre- and
post-eradication. An exacerbation was defined as an
episode of increased symptoms of bronchiectasis requiring
a course of oral or intravenous antibiotics. Data on antibi-
otic courses was obtained from hospital records and GP
prescriptions. A hospital admission was defined as an
increase in symptoms of bronchiectasis requiring admission
to hospital for intravenous antibiotics.
Spirometry
This was performed in the lung function laboratory using
a standard spirometer (ZAN 100, nSpire) at routine clinic
visits and was recorded as percentage predicted, based on
standard prediction charts.12
Statistical analysis
Comparison of parametric data was made using
Student’s t-test and of non-parametric data using the
Table 2 Use of intravenous antibiotics (A), ciprofloxacin
and nebulised colistin (B).
A
IV antibiotic regimea n
Ceftazidime þ gentamicin 17
Ceftazidime þ tobramycin 4
Ceftazidime þ colistin 1









Ciprofloxacin (oral regime, n Z 5) 1 0.25e4
Ciprofloxacin
(post-IV antibiotics, n Z 13)
1 0.5e3
Colistin (nebulised) (n Z 26b) 3 0.5e4
a Two-week course.
b Colistin continued long-term in 9 patients therefore median
duration relates to remaining 17 patients in whom colistin was
stopped.




30 patients were identified and characteristics are shown in
Table 1. Median follow-up timewas 26.4months. Themedian
number of sputum cultures per patient positive for Pseudo-
monas prior to treatment was 2.0 (range 1e9) with median
time from first positive culture to treatment of 7.2 months
(range 0.3e33.7 months). Computerised data on historical
sputum results was not available for 9 of the earliest cases.
Antibiotic regimes
25 patients received two weeks of intravenous anti-Pseu-
domonal antibiotics and following this, 13 patients also
received oral ciprofloxacin (Table 2A and B). The remaining
5 patients received oral ciprofloxacin without intravenous
antibiotics. Following intravenous and/or oral antibiotics,
25 patients received nebulised colistin. The reasons for the
5 patients not receiving colistin were intolerance of the
drug (n Z 3) and clinician’s decision (n Z 2). 9 patients
were maintained on regular nebulised colistin following
eradication therapy, nebulised antibiotics were restarted
within a year of eradication in a further 4 patients (colistin
nZ 2, gentamicin nZ 2), and restarted over one year from
eradication in 6 patients (colistin nZ 5, gentamicin nZ 1).
Pseudomonas eradication
Pseudomonas was initially eradicated from sputum in 24
patients (80%). 13/24 patients remained Pseudomonas-free
at their latest follow-up (median 14.3 months). 11/24
patients subsequently re-cultured Pseudomonas with
median time to reinfection 6.2 months (Fig. 1).Table 1 Patient characteristics.
Age (mean years  SD) 62.2  17.1
Male : Female 9:21




Smoking status Never 16
Ex 13
Current 1





Associated conditions Asthma 5
COPD 6
ABPA 3
Data are presented as number of patients, unless otherwise
stated. COPD Z chronic obstructive pulmonary disease,
ABPA Z allergic bronchopulmonary aspergillosis.Pseudomonas antibiotic sensitivities
Antibiotic sensitivities were recorded in the 11 patients in
whom Pseudomonas was initially eradicated, and who were
subsequently recolonised. In 6/11 patients, Pseudomonas
remained fully sensitive (including to ciprofloxacin)
following treatment. In four patients, new antibiotic
resistance occurred: aztreonam (n Z 1), ciprofloxacin
(n Z 1), ciprofloxacin and gentamicin (n Z 1), amikacin
and gentamicin (nZ 1). Sensitivities were not available for
one patient. One patient cultured MRSA and another Sten-
otrophomonas maltophilia following eradication therapy.
Exacerbations and admissions
Exacerbation frequency was significantly reduced, with
mean number of antibiotic courses 3.93 in the year pre-
eradication, and 2.09 in the year post-eradicationFigure 1 KaplaneMeier curve showing Pseudomonas-free
time following eradication therapy.
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were 0.39 in the year pre-eradication and 0.29 in the year
post-eradication (p Z NS). When divided into patients who
were Pseudomonas-free and those who were colonised,
there was a reduction in exacerbations in both groups
although it was only significant in the colonised group.
Admissions were reduced only in the Pseudomonas-free
group, but this did not reach significance.
Spirometry
Lung function remained unchanged, with mean percentage
predicted FEV1 62.1% pre- and 64.1% post-eradication
(p Z NS).
Discussion
To our knowledge this is the first study to assess the effects
of eradication therapy initiated after first colonisation of
Pseudomonas in non-CF bronchiectasis. Although previous
studies have studied use of nebulised antibiotics in this
patient population they have focussed on patients with
chronic, or established, Pseudomonas infection.13e17 The
results of this study suggest that early use of aggressive
antibiotic therapy may not only be initially more successful
in eradicating this organism, but may also have a beneficial
effect on subsequent exacerbation rates.
Early and aggressive use of antibiotics in our patient
population led to Pseudomonas eradication in 80% of
patients, with clearance maintained in 50% of cases at 12
months and 30% at 70 months. These eradication rates
compare favourably with other studies in which initial
eradication rates of just 22e35% were achieved.13,18 This
superior efficacy may relate to our use of a more aggressive
antibiotic regime at an earlier stage, although clearly an
alternative explanation may be that these patients simply
had less severe disease than those from previously reported
studies. In the majority of patients recolonised with Pseu-
domonas, the organism remained fully sensitive. In the four
patients in whom resistance developed, it was only to one
or two antibiotics, and therefore did not significantly affect
future treatment options.
Use of early eradication therapy in this study signifi-
cantly reduced exacerbation rates overall, suggesting that
this intervention also had a meaningful clinical impact on
disease behaviour. Subgroup analysis suggested a reduction
in exacerbations in both those who remained Pseudomonas-Table 3 Exacerbation and admission rates in the year pre and
Outcome Patient group Pre




Colonised (n Z 17) 4.4
Admissionsb All patients 0.39
Pseudomonas-free 0.46
Colonised 0.24
a Mean number of antibiotic courses per year.
b Mean number per year.free and those who were colonised, although only the
reduction in the latter group was statistically significant.
This apparent lack of significance in the Pseudomonas-free
group should be interpreted with caution given the small
numbers of patients involved. It is possible that the
reduction in exacerbations in those patients who remained
colonised may have been due to the effect of the subse-
quent long-term nebulised antibiotics, rather than eradi-
cation therapy itself, as this intervention has previously
been shown to reduce exacerbations.14
Overall admission rates in our study were not reduced
following eradication therapy. This is in contrast to previous
studies of nebulised antibiotics in chronic infection.15,16
However, our patient cohort had a low hospital admission
rate pre-eradication therapy, presumably because they
were in the earlier stages of their disease. Given this, it
would be more difficult to demonstrate an impact on
admission rates. There was a trend towards reduced
admissions in the group in which Pseudomonas had been
successfully eradicated, but this did not reach statistical
significance. Interpretation must be limited given the small
patient numbers and the potential confounder of a post-
antibiotic effect rather than eradication per se.
We acknowledge the limitations in this retrospective
study involving a relatively small number of patients.
Although there was a standardised Unit protocol for eradi-
cation therapy, treatment regimes varied between patients
making it difficult to draw definite conclusions about indi-
vidual antibiotic therapies. Nonetheless, the majority of
patients received intravenous and nebulised antibiotics for
two weeks and three months respectively, with cipro-
floxacin use accounting for the main differences. Although
not all patients received the same intravenous antibiotics,
all but two received two concurrent anti-Pseudomonal
agents, and thus efficacy is likely to be similar irrespective
of which antibiotic was used. These variations reflected
normal clinical practice, with reasons such as patient
preference regarding treatment regime and antibiotic side-
effects accounting for most deviations from protocol.
Although most patients received eradication therapy soon
after their first or second positive culture, there was a delay
in initiating therapy in somepatients. This reflected everyday
clinical practice as some of the latter group of patients had
less severe symptoms and elected not to undergo eradication
therapy initially. It was usual practice to collect samples
following completion of treatment. However, the timing of
subsequent sputum samples was usually at next point of








360 L. White et al.acknowledge that variations in timings of sample collection
may have affected the reported time to reinfection.
This retrospective study is prone to selection bias.
However, this is less likely as eradication therapy is well
established in our unit and offered to all patientswho culture
Pseudomonas. As the study was carried out in a District
General Hospital setting, we feel that our study population
was representative of the standard non-CF bronchiectatic
patient and thus applicable to everyday practice.
Pseudomonas infection in non-CF bronchiectasis is
a common clinical problem, yet there have been no rand-
omised controlled trials examining use of eradication
therapy in those recently infected. Instead current practice
is based on studies of treatment for chronic Pseudomonas
infection, data extrapolated from CF patients and expert
opinion. A prospective randomised controlled trial would
allow consistent treatment regimes, controlled timing of
sputum samples and more accurate data on symptoms.
Based on the results of this study, an intravenous and
nebulised antibiotic regime may be appropriate, with or
without additional ciprofloxacin. However, a more conser-
vative approach using ciprofloxacin and nebulised colistin,
the regime commonly used in CF, remains an alternative.
Despite its limitations this retrospective study provides
initial evidence that early Pseudomonas eradication
therapy in non-CF bronchiectasis may be effective.
Prospective randomised trials are now needed to answer
this important clinical question.Conflict of interest statement
There are no conflicts of interest for any of the authors.
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